NASDAQ$GEHC
GE HealthCare Technologies Inc · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
GE HealthCare reported Q1 2025 total revenues of $4.78B with net income attributable to GE HealthCare of $564M and diluted EPS of $1.23.
Total revenues were $4.78 billion for the quarter ended March 31, 2025, up 3% year over year. Net income attributable to GE HealthCare was $564 million ($1.23 diluted EPS) versus $374 million ($0.81 EPS) a year ago. Imaging and ultrasound demand, China recovery, and productivity programs supported margins while tariffs and China policy remain watch items.
- Q1 total revenues $4.78B (+3% YoY); segment EBIT growth across Imaging and Ultrasound.
- Net income to GE HealthCare $564M; diluted EPS $1.23.
- Orders and backlog trends support equipment and services mix.
- Tariffs, China demand, and FX remain EPS sensitivities.
Headline financials
Revenue & EPS history
GE HealthCare · Revenue · Quarterly
$4.78B
Revenue by segment
GE HealthCare · $4.01B total across 4 segments · Q3 2023
- Imaging$2.64B+4.7%65.8%
- Patient Care$764M+9.0%19.1%
- Pharma Diagnostics$589M+12.8%14.7%
- Other$19M+35.7%0.5%
Forward guidance
The quarterly filing discusses operating priorities, liquidity, and sector risks.
Tailwinds
- MD&A outlines strategic priorities and capital allocation.
- Segment commentary supports the earnings narrative.
Headwinds
- Macro, rates, or input costs may pressure margins.
- One-time items can affect year-over-year comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q1 2025
-0.2%
Avg return
Earnings day
+0.2%
Avg return
5 days after
-0.3%
Avg return
30 days after
50%
8 / 16 earnings
Positive
+11.5%
Q4 2021
Best reaction
-12.9%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -12.9% | -10.9% | -8.9% | |
| Q4 2025 | +6.4% | +0.4% | -5.7% | |
| Q3 2025 | -2.7% | -6.2% | +0.7% | |
| Q1 2025 | +3.3% | +1.9% | +3.6% | |
| Q4 2024 | +8.8% | +7.9% | -4.6% | |
| Q3 2024 | +2.4% | +2.0% | -2.4% | |
| Q2 2024 | +0.9% | -1.4% | +2.6% | |
| Q1 2024 | -12.0% | -10.6% | -11.7% | |
| Q4 2021 | +11.5% | +10.8% | +26.2% | |
| Q3 2023 | +8.1% | +13.3% | +8.4% | |
| Q3 2022 | +8.1% | +13.3% | +8.4% | |
| Q2 2023 | -4.0% | -3.4% | -15.1% | |
| Q1 2023 | -8.7% | -7.3% | -9.0% | |
| Q1 2022 | -8.7% | -7.3% | -9.0% | |
| Q2 2022 | -2.3% | +0.8% | +4.4% | |
| Q4 2022 | -0.8% | +0.7% | +7.4% | |
| Q3 2021 | — | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro